Key result
Transcatheter tricuspid annuloplasty using the K-Clip system resulted in 0% 30-day mortality and reduced TR severity by at least one grade in 100% of patients.
Why the study?
Surgery for isolated functional TR poses high risk, and the utility of the percutaneous K-Clip system remains unknown.
Does transcatheter tricuspid annuloplasty with the K-Clip system improve clinical outcomes and reduce TR severity in patients with severe functional tricuspid regurgitation at high surgical risk?
Does transcatheter tricuspid annuloplasty with the K-Clip system improve clinical outcomes and reduce TR severity in patients with severe functional tricuspid regurgitation at high surgical risk?
Transcatheter tricuspid annuloplasty using the K-Clip system is safe and effectively reduces TR severity while improving functional status and quality of life at 30 days in high-risk patients.
Answers are grounded in this paper and cite their sources.
Supports short-term safety/efficacy of K-Clip in high-risk TR; leaves open durability and need for RCTs before practice change.
Surgery for isolated functional tricuspid regurgitation (TR) poses a high risk. Several transcatheter approaches are being evaluated for the treatment of such patients. The K-Clip system is a percutaneous approach designed for functional TR; however, its utility remains unknown. This study aimed to report the 30-day echocardiographic and clinical outcomes with the K-Clip system for severe TR, including changes in TR severity and NYHA functional class. Transcatheter tricuspid valve annuloplasty was performed in 39 patients with intermediate or high surgical risk who underwent the K-Clip system. The right internal jugular vein procedure was performed with annuloplasty guided by fluoroscopy and echocardiography. The primary outcomes were clinical success and all-cause mortality at the 30-day follow-up. The K-Clip was successfully implanted in all cases, with 1 to 3 devices deployed. At the 30-day follow-up, none of the patients had died. TR severity was reduced by at least one grade in all patients. There were no severe procedural or 30-day adverse events, except for 1 new pacemaker implantation. The proportion of New York Heart Association class III-IV patients decreased from 79.5% to 5.1%, and the ascites disappeared. The 6-minute walk distance increased by 78 m (P < 0.05), and the Kansas City Cardiomyopathy Questionnaire score improved by 11 points (P < 0.05). The K-Clip device is practical, safe, and effective for patients with severe TR. A 30-day reduction in TR and enhanced cardiac function and quality of life were associated with transcatheter tricuspid annuloplasty using the K-Clip device, according to short-term follow-up studies. (Confirmatory Clinical Study of Treating Tricuspid Regurgitation With K-Clip TM Transcatheter Annuloplasty System [TriStar]; NCT05173233)
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) studied severe functional tricuspid regurgitation (n=39). K-Clip system was evaluated on clinical success and all-cause mortality at 30 days. Transcatheter tricuspid annuloplasty using the K-Clip system resulted in 0% 30-day mortality and reduced TR severity by at least one grade in 100% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: